BackPoniard Pharmaceuticals Overview

Poniard Pharmaceuticals EBIT

Latest ebit for PARD: $-16M, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$3.75M
↑ 37.02% YoY

As of Sep 30, 2011

Annual EBIT (TTM)

-$15.53M
↑ 52.32% YoY

Trailing 12 months ending Sep 30, 2011

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Poniard Pharmaceuticals (PARD) FAQ

Poniard Pharmaceuticals (PARD) currently reports a EBIT of $-16M as of September 2011. That compares with $-33M in the prior-year period — up 52.3% year over year. That is below the Healthcare sector average of $1.9T. Use the charts on this page to explore Poniard Pharmaceuticals's EBIT history and peer comparisons.

Poniard Pharmaceuticals's EBIT increased from $-33M to $-16M — a 52.3% year-over-year increase (period ending September 2011). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Poniard Pharmaceuticals's EBIT of $-16M is lower than the Healthcare sector average of $1.9T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Poniard Pharmaceuticals reported $-16M in EBIT as of September 2011. That compares with $-33M in the prior-year period — up 52.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-16M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $1.9T. From there, open related valuation or income-statement pages for Poniard Pharmaceuticals, and consider following PARD for alerts when major investors trade the stock.